Neurology Live, a clinical neurologists focused media portal based in USA, has published GN Corporation’s presentation at the MDA – Muscular Dystrophy Association Conference 2023 on the Clinical trial results of Neu REFIX in Duchenne Muscular Dystrophy.
The six-months long clinical trial in which Neu REFIX, one of the Nichiglucan brand products, was used in combination with the standard care medication, is reported to safely slowing down the progress of DMD.
At the MDA’s muscular dystrophy conference in Dallas, Texas, USA between March 19-22, GN Corporation also presented the outcome of a pre-clinical study in which the MDX mice fed with N-163 strain of Aureobasidium Pullulans produced Beta glucans, the Neu REFIX, showed improvement of skeletal muscle regeneration, proven by relevant biomarkers.
